{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-286829","form_type":"8-K","ticker":"ZYME","cik":"0001937653","company_name":"Zymeworks Inc.","filed_at":"2026-06-29T11:20:20+00:00","discovered_at":"2026-06-29T11:25:00.207548+00:00","generated_at":"2026-06-29T11:25:19.246175+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"confidence":"high","headline":"Zymeworks to acquire Theravance Biopharma for $17/share (~$929M total cash consideration)","bullets":["Deal adds YUPELRI (revefenacin) with ~$60M annualized cash flow from 35% U.S. profit share","Financing: $350M non-recourse note from OMERS Life Sciences, plus Zymeworks cash and Theravance's ~$360M net cash at close","Shareholders receive $17 cash plus one CVR per share tied to ampreloxetine monetization (80% of net proceeds to CVR holders)","Zymeworks expects $100M Trelegy milestone from Royalty Pharma in Q1 2027; also retains ~$2.5B Irish tax attributes","Transaction expected to close in H2 2026; Zymeworks also maintains up to $125M share repurchase program"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-286829","json":"https://secwatch.observer/filing/0001193125-26-286829.json","markdown":"https://secwatch.observer/filing/0001193125-26-286829.md","text":"https://secwatch.observer/filing/0001193125-26-286829.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1937653/000119312526286829/0001193125-26-286829-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1937653/000119312526286829/d156494d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T11:25:19.246175+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}